165 related articles for article (PubMed ID: 22759318)
1. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody.
Poirier N; Mary C; Dilek N; Hervouet J; Minault D; Blancho G; Vanhove B
Am J Transplant; 2012 Oct; 12(10):2630-40. PubMed ID: 22759318
[TBL] [Abstract][Full Text] [Related]
2. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28.
Poirier N; Mary C; Le Bas-Bernardet S; Daguin V; Belarif L; Chevalier M; Hervouet J; Minault D; Ville S; Charpy V; Blancho G; Vanhove B
MAbs; 2014; 6(3):697-707. PubMed ID: 24598534
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.
Poirier N; Blancho G; Hiance M; Mary C; Van Assche T; Lempoels J; Ramael S; Wang W; Thepenier V; Braudeau C; Salabert N; Josien R; Anderson I; Gourley I; Soulillou JP; Coquoz D; Vanhove B
J Immunol; 2016 Dec; 197(12):4593-4602. PubMed ID: 27849166
[TBL] [Abstract][Full Text] [Related]
4. FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft.
Poirier N; Dilek N; Mary C; Ville S; Coulon F; Branchereau J; Tillou X; Charpy V; Pengam S; Nerriere-Daguin V; Hervouet J; Minault D; Le Bas-Bernardet S; Renaudin K; Vanhove B; Blancho G
Am J Transplant; 2015 Jan; 15(1):88-100. PubMed ID: 25488654
[TBL] [Abstract][Full Text] [Related]
5. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates.
Watkins BK; Tkachev V; Furlan SN; Hunt DJ; Betz K; Yu A; Brown M; Poirier N; Zheng HB; Taraseviciute A; Colonna L; Mary C; Blancho G; Soulillou JP; Panoskaltsis-Mortari A; Sharma P; Garcia A; Strobert E; Hamby K; Garrett A; Deane T; Blazar BR; Vanhove B; Kean LS
J Clin Invest; 2018 Aug; 128(9):3991-4007. PubMed ID: 30102255
[TBL] [Abstract][Full Text] [Related]
6. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody.
Vanhove B; Laflamme G; Coulon F; Mougin M; Vusio P; Haspot F; Tiollier J; Soulillou JP
Blood; 2003 Jul; 102(2):564-70. PubMed ID: 12649149
[TBL] [Abstract][Full Text] [Related]
7. Selective blockade of CD28-mediated T cell costimulation protects rhesus monkeys against acute fatal experimental autoimmune encephalomyelitis.
Haanstra KG; Dijkman K; Bashir N; Bauer J; Mary C; Poirier N; Baker P; Crossan CL; Scobie L; 't Hart BA; Vanhove B
J Immunol; 2015 Feb; 194(4):1454-66. PubMed ID: 25589073
[TBL] [Abstract][Full Text] [Related]
8. Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain.
Mary C; Coulon F; Poirier N; Dilek N; Martinet B; Blancho G; Vanhove B
MAbs; 2013; 5(1):47-55. PubMed ID: 23221503
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.
Ville S; Poirier N; Branchereau J; Charpy V; Pengam S; Nerriere-Daguin V; Le Bas-Bernardet S; Coulon F; Mary C; Chenouard A; Hervouet J; Minault D; Nedellec S; Renaudin K; Vanhove B; Blancho G
J Am Soc Nephrol; 2016 Dec; 27(12):3577-3588. PubMed ID: 27160407
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.
Hippen KL; Watkins B; Tkachev V; Lemire AM; Lehnen C; Riddle MJ; Singh K; Panoskaltsis-Mortari A; Vanhove B; Tolar J; Kean LS; Blazar BR
Transplantation; 2016 Dec; 100(12):2630-2639. PubMed ID: 27861291
[TBL] [Abstract][Full Text] [Related]
11. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile.
Broeren CP; Gray GS; Carreno BM; June CH
J Immunol; 2000 Dec; 165(12):6908-14. PubMed ID: 11120816
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses.
Haspot F; Villemain F; Laflamme G; Coulon F; Olive D; Tiollier J; Soulillou JP; Vanhove B
Blood; 2002 Mar; 99(6):2228-34. PubMed ID: 11877302
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantation.
Graves SS; Stone DM; Loretz C; Peterson LJ; Lesnikova M; Hwang B; Georges GE; Nash R; Storb R
Transplantation; 2011 Apr; 91(8):833-40. PubMed ID: 21343872
[TBL] [Abstract][Full Text] [Related]
14. Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses.
Zaitsu M; Issa F; Hester J; Vanhove B; Wood KJ
JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978798
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
Guo Z; Wu T; Kirchhof N; Mital D; Williams JW; Azuma M; Sutherland DE; Hering BJ
Transplantation; 2001 Jun; 71(11):1656-65. PubMed ID: 11435979
[TBL] [Abstract][Full Text] [Related]
16. CD28-specific antibody prevents graft-versus-host disease in mice.
Yu XZ; Bidwell SJ; Martin PJ; Anasetti C
J Immunol; 2000 May; 164(9):4564-8. PubMed ID: 10779758
[TBL] [Abstract][Full Text] [Related]
17. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
[TBL] [Abstract][Full Text] [Related]
18. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.
Krummel MF; Sullivan TJ; Allison JP
Int Immunol; 1996 Apr; 8(4):519-23. PubMed ID: 8671638
[TBL] [Abstract][Full Text] [Related]
19. A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice.
Besançon A; Goncalves T; Valette F; Mary C; Vanhove B; Chatenoud L; You S
Diabetologia; 2018 Aug; 61(8):1811-1816. PubMed ID: 29845333
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression.
Gao C; Gardner D; Theobalds MC; Hitchcock S; Deutsch H; Amuzie C; Cesaroni M; Sargsyan D; Rao TS; Malaviya R
Clin Exp Immunol; 2021 Dec; 206(3):422-438. PubMed ID: 34487545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
